About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 849504, 9 pages
http://dx.doi.org/10.1155/2013/849504
Review Article

Treatment of Chagas Cardiomyopathy

1Postgraduate Course of Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, 30130 100 Belo Horizonte, MG, Brazil
2Hospital das Clínicas, Universidade Federal de Minas Gerais, 30130 100 Belo Horizonte, MG, Brazil
3Fundação Hospitalar do Estado de Minas Gerais, 30150 260 Belo Horizonte, MG, Brazil
4School of Medicine, Universidade Federal de Ouro Preto, 35400 000 Ouro Preto, MG, Brazil
5Departamento de Fisioterapia, Universidade Federal do Vale do Mucuri e Jequitinhonha, 39100 000 Diamantina, MG, Brazil

Received 30 April 2013; Revised 17 September 2013; Accepted 17 September 2013

Academic Editor: Christof Kolb

Copyright © 2013 Fernando A. Botoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Chagas disease: control and elimination. (A63/17), 2010, http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_17-en.pdf.
  2. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases, 2010, http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf.
  3. C. Beyrer, J. C. Villar, V. Suwanvanichkij, S. Singh, S. D. Baral, and E. J. Mills, “Neglected diseases, civil conflicts, and the right to health,” The Lancet, vol. 370, no. 9587, pp. 619–627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Maguire, “Chagas' disease—can we stop the deaths?” The New England Journal of Medicine, vol. 355, no. 8, pp. 760–761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Chagas disease (American trypanosomiasis). Fact sheet N°340. June 2010, http://www.who.int/mediacentre/factsheets/fs340/en/.
  6. A. L. Ribeiro, M. P. Nunes, M. M. Teixeira, and M. O. Rocha, “Diagnosis and management of Chagas disease and cardiomyopathy,” Nature Reviews Cardiology, vol. 9, no. 10, pp. 576–589, 2012. View at Publisher · View at Google Scholar
  7. C. Mady, R. H. A. Cardoso, A. C. P. Barretto, P. L. Da Luz, G. Bellotti, and F. Pileggi, “Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy,” Circulation, vol. 90, no. 6, pp. 3098–3102, 1994. View at Scopus
  8. L. A. Cubillos-Garzón, J. P. Casas, C. A. Morillo, and L. E. Bautista, “Congestive heart failure in Latin America: the next epidemic,” American Heart Journal, vol. 147, no. 3, pp. 412–417, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. L. Higuchi, L. A. Benvenuti, M. M. Reis, and M. Metzger, “Pathophysiology of the heart in Chagas' disease: current status and new developments,” Cardiovascular Research, vol. 60, no. 1, pp. 96–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Andrade, J. A. Marin-Neto, A. A. Paola, et al., “Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica,” Arquivos Brasileiros de Cardiologia, vol. 97, no. 2, supplement 3, pp. 1–48, 2011.
  11. F. S. Machado, L. A. Jelicks, L. V. Kirchhoff et al., “Chagas heart disease: report on recent developments,” Cardiology in Review, vol. 20, no. 2, pp. 53–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Marin-Neto, E. Cunha-Neto, B. C. Maciel, and M. V. Simões, “Pathogenesis of chronic Chagas heart disease,” Circulation, vol. 115, no. 9, pp. 1109–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Rassi Jr., A. Rassi, W. C. Little et al., “Development and validation of a risk score for predicting death in Chagas' heart disease,” The New England Journal of Medicine, vol. 355, no. 8, pp. 799–808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. P. Ribeiro, P. S. Cavalvanti, F. Lombardi, M. D. C. P. Nunes, M. V. L. Barros, and M. O. D. C. Rocha, “Prognostic value of signal-averaged electrocardiogram in Chagas disease,” Journal of Cardiovascular Electrophysiology, vol. 19, no. 5, pp. 502–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. B. Bestetti, C. M. R. Dalbo, O. C. Freitas, L. A. C. Teno, O. T. Castilho, and J. S. M. Oliveira, “Noninvasive predictors of mortality for patients with Chagas' heart disease: a multivariate stepwise logistic regression study,” Cardiology, vol. 84, no. 4-5, pp. 261–267, 1994. View at Scopus
  16. A. Rassi Jr., A. Rassi, and S. G. Rassi, “Predictors of mortality in chronic Chagas disease. A systematic review of observational studies,” Circulation, vol. 115, no. 9, pp. 1101–1108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Dias, F. S. Laranja, and G. Nobrega, “Doenca de Chagas,” Memórias do Instituto Oswaldo Cruz, vol. 42, pp. 530–545, 1945.
  18. L. Bogliolo, “Anatomie causes of cardiac insufficiency in chronic chagasic cardiopathy (myocarditis) studied in comparison to anatomic causes of cardiac insufficiency in other cardiopathies. Part I,” Arquivos Brasileiros de Cardiologia, vol. 29, pp. 419–424, 1976.
  19. R. B. Bestetti and G. Muccillo, “Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy,” International Journal of Cardiology, vol. 60, no. 2, pp. 187–193, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. R. R. Roberti, E. E. Martinez, J. L. Andrade et al., “Chagas cardiomyopathy and captopril,” European Heart Journal, vol. 13, no. 7, pp. 966–970, 1992. View at Scopus
  21. A. M. Khoury, D. F. Davila, G. Bellabarba et al., “Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure,” International Journal of Cardiology, vol. 57, no. 1, pp. 21–29, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Freitas, G. Salatino, P. Chizzola, et al., “β-blockers for Chagas's heart disease: the reduction in heart rate may not be associated to improvement in left ventricular ejection fraction and remodeling process,” Journal of the American College of Cardiology, abstracts 184 A—Heart Failure, 1999.
  23. D. F. Davila, F. Angel, G. Arata de Bellabarba, et al., “Effects of metoprolol in chagasic patients with severe congestive heart failure,” International Journal of Cardiology, vol. 85, no. 2, pp. 255–260, 2002. View at Publisher · View at Google Scholar
  24. C. D. Alberquerque, M. Batlouni, R. M. Rocha, and on Behalf of Accordes Trial Investigators, “ACCORDES Trial—Brazilian open label study with carvedilol to demonstrate efficacy in chronic heart failure, including a pilot subgroup with Chagas disease,” Journal of Cardiac Failure, vol. 9, no. 5, supplement 1, p. S58, 2003. View at Publisher · View at Google Scholar
  25. F. A. Botoni, P. A. Poole-Wilson, A. L. P. Ribeiro et al., “A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy,” American Heart Journal, vol. 153, no. 4, pp. 544.e1–544.e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. B. Bestetti, T. A. D. Theodoropoulos, and A. Cardinalli-Neto, “Treating patients with Chagas' cardiomyopathy with chronic heart failure in the contemporary era,” American Heart Journal, vol. 154, no. 5, p. e35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Bocchi, F. Cruz, G. Guimarães et al., “Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial,” Circulation, vol. 1, no. 2, pp. 115–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. V. S. Issa, A. F. Amaral, F. D. Cruz et al., “β-Blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial,” Circulation, vol. 3, no. 1, pp. 82–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Pinazo, D. Tàssies, J. Muñoz, et al., “Hypercoagulability biomarkers in Trypanosoma cruzi infected patients,” Thromb Haemost, vol. 106, no. 4, pp. 617–623, 2011. View at Publisher · View at Google Scholar
  30. A. Rassi Jr., S. G. Rassi, and A. Rassi, “Sudden death in Chagas' disease,” Arquivos Brasileiros de Cardiologia, vol. 76, no. 1, pp. 86–96, 2001. View at Scopus
  31. P. A. Chiale, M. S. Halpern, and G. J. Nau, “Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis,” American Heart Journal, vol. 107, no. 4, pp. 656–665, 1984. View at Scopus
  32. A. H. Haedo, P. A. Chiale, and J. D. Bandieri, “Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms,” Journal of the American College of Cardiology, vol. 7, no. 5, pp. 1114–1120, 1986. View at Scopus
  33. M. Rosenbaum, R. Posse, H. Sgammini, et al., “Comparative multicenterclinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy,” Archivos del Instituto de Cardiología de México, vol. 57, no. 4, pp. 325–330, 1987.
  34. M. Scanavacca and E. Sosa, “Electrophysiologic study in chronic Chagas' heart disease,” São Paulo Medical Journal, vol. 113, no. 2, pp. 841–850, 1995. View at Scopus
  35. E. B. Sternick, M. Martinelli, R. C. Sampaio et al., “Sudden cardiac death in patients with Chagas heart disease and preserved left ventricular function,” Journal of Cardiovascular Electrophysiology, vol. 17, no. 1, pp. 113–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Martinelli, S. F. de Siqueira, E. B. Sternick, et al., “Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in Chagas' heart disease,” Am J Cardiol, vol. 110, no. 7, pp. 1040–1045, 2012. View at Publisher · View at Google Scholar
  37. M. P. Barbosa, M. O. da Costa Rocha, A. B. de Oliveira, F. Lombardi, and A. L. Ribeiro, “Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease,” Europace, vol. 15, no. 7, pp. 957–962, 2013. View at Publisher · View at Google Scholar
  38. A. Cardinalli-Neto, O. T. Greco, and R. B. Bestetti, “Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias,” Pacing and Clinical Electrophysiology, vol. 29, no. 5, pp. 467–470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Cardinalli-Neto, R. B. Bestetti, J. A. Cordeiro, and V. C. Rodrigues, “Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy,” Journal of Cardiovascular Electrophysiology, vol. 18, no. 12, pp. 1236–1240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. L. R. Leite, G. Fenelon, A. Simoes Jr., G. G. Silva, P. A. Friedman, and A. A. V. de Paola, “Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol,” Journal of Cardiovascular Electrophysiology, vol. 14, no. 6, pp. 567–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. B. D. Henz, T. A. do Nascimento, C. D. O. Dietrich et al., “Simultaneous epicardial and endocardial substrate mapping and radiofrequency catheter ablation as first-line treatment for ventricular tachycardia and frequent ICD shocks in chronic chagasic cardiomyopathy,” Journal of Interventional Cardiac Electrophysiology, vol. 26, no. 3, pp. 195–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. C. A. Muratore and A. Baranchuk, “Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy,” Vascular Health and Risk Management, vol. 6, no. 1, pp. 593–601, 2010. View at Scopus
  43. U. Ikeda, H. Kasai, A. Izawa et al., “Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure,” Current Cardiology Reviews, vol. 4, no. 3, pp. 219–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Dandel, G. Wallukat, A. Englert, and R. Hetzer, “Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension,” Atherosclerosis Supplements, vol. 14, no. 1, pp. 203–211, 2013. View at Publisher · View at Google Scholar
  45. V. Labovsky, C. R. Smulski, K. Gómez, G. Levy, and M. J. Levin, “Anti-β1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease,” Clinical and Experimental Immunology, vol. 148, no. 3, pp. 440–449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Haberland, S. G. Saravia, G. Wallukat, R. Ziebig, and I. Schimke, “Chronic Chagas disease: from basics to laboratory medicine,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 2, pp. 271–294, 2013.
  47. A. Haberland, G. Wallukat, and I. Schimke, “Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment,” Trends in Cardiovascular Medicine, vol. 21, no. 6, pp. 177–182, 2011. View at Publisher · View at Google Scholar
  48. M. B. P. Soares and R. R. dos Santos, “Current status and perspectives of cell therapy in Chagas disease,” Memorias do Instituto Oswaldo Cruz, vol. 104, supplement 1, pp. 325–332, 2009. View at Scopus
  49. A. C. Campos de Carvalho, R. C. Goldenberg, L. A. Jelicks et al., “Cell therapy in Chagas disease,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2009, Article ID 484358, 6 pages, 2009. View at Publisher · View at Google Scholar
  50. F. Vilas-Boas, G. S. Feitosa, M. B. P. Soares et al., “Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease,” Arquivos Brasileiros de Cardiologia, vol. 87, no. 2, pp. 159–166, 2006. View at Scopus
  51. B. R. Tura, H. F. Martino, L. H. Gowdak et al., “Multicenter randomized trial of cell therapy in cardiopathies—MiHeart study,” Trials, vol. 8, article 2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Ribeiro dos Santos, S. Rassi, G. Feitosa et al., “Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial,” Circulation, vol. 125, no. 20, pp. 2454–2461, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Ieda, J. D. Fu, P. Delgado-Olguin et al., “Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors,” Cell, vol. 142, no. 3, pp. 375–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Lannes-Vieira, J. C. Silverio, I. R. Pereira et al., “Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokine receptors—how to make a dream come true,” Memorias do Instituto Oswaldo Cruz, vol. 104, supplement 1, pp. 226–235, 2009. View at Scopus
  55. R. B. Bestetti and T. A. D. Theodoropoulos, “A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease,” Journal of Cardiac Failure, vol. 15, no. 3, pp. 249–255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. L. F. P. Moreira, J. Galantier, A. Benício, A. A. Leirner, I. A. Cestari, and N. A. G. Stolf, “Left ventricular circulatory support as bridge to heart transplantation in Chagas' disease cardiomyopathy,” Artificial Organs, vol. 31, no. 4, pp. 253–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. M. M. O. Lima, M. O. C. Rocha, M. C. P. Nunes et al., “A randomized trial of the effects of exercise training in Chagas cardiomyopathy,” European Journal of Heart Failure, vol. 12, no. 8, pp. 866–873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. D. C. P. Nunes, F. R. Beloti, M. M. O. Lima et al., “Functional capacity and right ventricular function in patients with Chagas heart disease,” European Journal of Echocardiography, vol. 11, no. 7, pp. 590–595, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. M. O. Lima, M. C. P. Nunes, M. O. C. Rocha, F. R. Beloti, M. C. N. Alencar, and A. L. P. Ribeiro, “Left ventricular diastolic function and exercise capacity in patients with Chagas cardiomyopathy,” Echocardiography, vol. 27, no. 5, pp. 519–524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. J. R. Coura and J. Borges-Pereira, “Chronic phase of Chagas disease: why should it be treated? A comprehensive review,” Memorias do Instituto Oswaldo Cruz, vol. 106, no. 6, pp. 641–645, 2011. View at Scopus
  61. A. L. Andrade, F. Zicker, R. M. Oliveira et al., “Randomised trial efficacy of benznidazole in the treatment of early Trypanosoma cruzi infection,” The Lancet, vol. 318, no. 9039, pp. 1407–1413, 1996. View at Publisher · View at Google Scholar
  62. S. Sosa-Estani, E. L. Segura, A. M. Ruiz, B. M. Porcel, and C. Yampotis, “Efficacy of chemotherapy with benznidazole in children in the intermediate phase of Chagas disease,” The American Journal of Tropical Medicine and Hygiene, vol. 59, pp. 526–529, 1998.
  63. J. A. Marin-Neto, A. Rassi Jr., C. A. Morillo et al., “Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT),” American Heart Journal, vol. 156, no. 1, pp. 37–43, 2008. View at Publisher · View at Google Scholar · View at Scopus